Treatment Intensification Gains Momentum in mCSPC Management
During a recent OncLive Peer Exchange, prostate cancer experts discussed the evolving role of treatment intensification in mCSPC.
Treatment Intensification in mCSPC: Key TakeawaysADT monotherapy is no longer sufficient for many patients with mCSPC; data from several phase 3 studies have demonstrated that intensification beyond ADT improves efficacy outcomes.Since no head-to-head comparisons between ARPIs in randomized clinical trials are available, ARPI selection must be individualized.Real-world evidence should be used to supplement clinical trial data in treatment selection decision making.
comments(0)
5-min edit window · permanent after that